Geron (GERN) Stock Price, News & Analysis

Company Overview

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes. Imetelstat works by directly binding to the RNA template of telomerase, thereby blocking the enzyme’s activity and shortening telomeres in malignant cells. Preclinical studies have also explored potential applications of telomerase inhibition in various solid tumors.

Founded in 1990 by researchers Elizabeth Blackburn, Carol Greider and Jack Szostak—who later received the Nobel Prize in Physiology or Medicine for their work on telomeres—Geron is headquartered in Foster City, California. The company has established collaborations and licensing agreements with academic institutions, contract research organizations and pharmaceutical partners to advance its clinical programs and expand its research capabilities.

Under the leadership of CEO John A. Scarlett, Geron continues to build its infrastructure for late-stage clinical development. The company serves a global community of physicians, researchers and patients by conducting multi-center clinical trials across North America and Europe, with the goal of bringing telomerase-targeted therapies to market.

Key Stats

• Today's Range: $1.25 to $1.29
• 50-Day Range: $1.22 to $1.77
• 52-Week Range: $1.04 to $2.01
• Volume: 6.86 million shs
• Average Volume: 16.57 million shs
• Market Capitalization: $821.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.50
• Consensus Rating: Hold

Geron Stock Analysis - MarketRank™

Geron scored higher than 45% of companies evaluated by MarketBeat, and ranked 620th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Geron has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 2 sell ratings.

Upside Potential

Geron has a consensus price target of $2.50, representing about 97.6% upside from its current price of $1.27.

Amount of Analyst Coverage

Geron has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Geron are expected to grow in the coming year, from ($0.02) to $0.10 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Geron is -11.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Geron is -11.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Geron has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.00% of the float of Geron has been sold short.

Short Interest Ratio / Days to Cover

Geron has a short interest ratio ("days to cover") of 5.52.

Change versus previous month

Short interest in Geron has recently decreased by 7.86%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Geron does not currently pay a dividend.

Dividend Growth

Geron does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.15

News Sentiment

Geron has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Geron this week, compared to 5 articles on an average week.

Search Interest

Only 9 people have searched for GERN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

8 people have added Geron to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Geron insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.71% of the stock of Geron is held by insiders.

Percentage Held by Institutions

73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 5/22/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GERN
• Previous Symbol: NASDAQ:GERN
• CIK: 886744
• Web: www.geron.com
• Phone: (650) 473-7700
• Fax: 650-473-7750
• Employees: 70
• Year Founded: 1990

Price Target and Rating

• Average Price Target for Geron: $2.50
• High Price Target: $4.00
• Low Price Target: $1.00
• Potential Upside/Downside: +95.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.50 million
• Net Margins: -35.48%
• Pretax Margin: -34.32%
• Return on Equity: -23.31%
• Return on Assets: -10.08%

Debt

• Debt-to-Equity Ratio: 0.52
• Current Ratio: 6.78
• Quick Ratio: 4.96

Sales & Book Value

• Annual Sales: $196.12 million
• Price / Sales: 4.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.36 per share
• Price / Book: 3.56

Miscellaneous

• Outstanding Shares: 641,521,000
• Free Float: 630,551,000
• Market Cap: $821.15 million
• Optionable: Optionable
• Beta: 0.68